Neutrisci Announces Successful Completion of Phase 1 R&D Dev

Neutrisci Announces Successful Completion of Phase 1 R&D Development of a Cannabinol Product


Neutrisci Announces Successful Completion of Phase 1 R&D Development of a Cannabinol Product
ACCESSWIRE
VANCOUVER, BC / ACCESSWIRE / May 10, 2021 / NeutriSci International Inc.
('NeutriSci' or the 'Company')
(TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce the Phase 1 R&D completion of a newly developed Cannabinol (CBN) product for the US marketplace. In conjunction with its contract manufacturing partner Pacwest, the completion of Phase 1 used NeutriSci's IP, technologies, and ingredients to create a finished CBN tablet product.
CBN is known for is its 'sleepiness effect.' When taken, it is known to cause drowsiness. Sleep problems are widespread in modern society. According to the Center for Disease Control, one in three adults do not get enough sleep. Sleep-deprived individuals are more likely to suffer from the most damaging health problems of the modern world, including coronary heart disease, cancer, and arthritis.

Related Keywords

United States , Vancouver , British Columbia , Canada , Americans , American , Glen Rehman , American Sleep Apnea Association , Drug Administration , Regulation Services Provider , Venture Exchange , Neutrisci International Inc , Neutrisci International , Disease Control , Chain Drug , Mass Market , ஒன்றுபட்டது மாநிலங்களில் , வான்கூவர் , பிரிட்டிஷ் கொலம்பியா , கனடா , அமெரிக்கர்கள் , அமெரிக்கன் , க்ளென் ரெஹ்மான் , அமெரிக்கன் தூங்கு மூச்சுத்திணறல் சங்கம் , ஒழுங்குமுறை சேவைகள் வழங்குநர் , துணிகர பரிமாற்றம் , நோய் கட்டுப்பாடு , சங்கிலி மருந்து , நிறை சந்தை ,

© 2025 Vimarsana